ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
97 506,33
-0,26%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC

  6. Astellas Pharma Inc (PK) (ALPMY) Cours

Astellas Pharma Inc (PK)

Astellas Pharma Inc (PK) (ALPMY)

USOTC
9,79
0,14
(1,45%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
9,79
Prix Achat
9,63
Prix Vente
10,00
Volume échangé
375 451
9,48 Fourchette du Jour 10,00
9,15 Plage de 52 semaines 13,14
Cap du marché
17,717B
Clôture Veille
9,65
Ouverture
10,00
Dernière Transaction
5
@
9.79
Dernière heure de transaction
Volume financier
US$ 3 687 889
VWAP
9,8226
Volume moyen (3 m)
180 430
Actions en circulation
1 809 663 075
Rendement du Dividende
5.04%
Ratio Cours sur Bénéfices
1,09
Bénéfice par action (BPA)
9,42
Chiffre d'affairess
1,62T
Bénéfice net
17,05B

À propos de Astellas Pharma Inc (PK)

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Diversified
Site Web
www.astellas.com
Siège social
Chuo, Tokyo, Jpn
Fondé
1984
Astellas Pharma Inc (PK) est coté dans le secteur Pharmaceutical Preparations de la OTCMarkets avec le ticker ALPMY. Le dernier cours de clôture d'Astellas Pharma (PK) était de US$9,65. Au cours de la dernière année, les actions de Astellas Pharma (PK) ont été négociées dans une fourchette de prix de US$ 9,15 à US$ 13,14.

Astellas Pharma (PK) compte actuellement 1 809 663 075 actions en circulation. La capitalisation boursière d'Astellas Pharma (PK) est de US$17,46 milliard. Astellas Pharma (PK) a un ratio cours/bénéfice (ratio PE) de 1.09.

ALPMY Dernières nouvelles

Plus de nouvelles

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award PR Newswire NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015 NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015...

04 Juin 2015
PR Newswire (US)

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Mee...

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting PR Newswire TOKYO and NORTHBROOK, Ill., June 1, 2015 TOKYO and...

01 Juin 2015
PR Newswire (US)

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refr...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) - Results from Phase 1/2 trial...

30 Mai 2015
PR Newswire (US)

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Tria...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial Data Presented in Plenary Session at AUA 2015 PR Newswire TOKYO and...

17 Mai 2015
PR Newswire (US)

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting PR Newswire TOKYO and SAN FRANCISCO, May 17, 2015 TOKYO and SAN...

17 Mai 2015
PR Newswire (US)

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be...

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting PR Newswire NORTHBROOK, Ill...

14 Mai 2015
PR Newswire (US)

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting PR Newswire NORTHBROOK, Ill., May 5, 2015 NORTHBROOK, Ill., May 5, 2015 /PRNewswire/...

05 Mai 2015
PR Newswire (US)

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics Exclusive Collaboration Includes Option for Astellas to Acquire Potenza PR Newswire TOKYO and...

22 Avril 2015
PR Newswire (US)

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function PR Newswire TOKYO, April 6, 2015 TOKYO, April 6, 2015 /PRNewswire/ -- Astellas ("Astellas,") (Tokyo: 4503) today announced...

06 Avril 2015
PR Newswire (US)

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia PR Newswire TOKYO and HOUSTON, April 3, 2015 TOKYO and HOUSTON, April 3, 2015...

03 Avril 2015
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.395-3.8782523318610.18510.219.414260909.81240104DR
40.060.6166495375139.7311.039.4129422310.18538734DR
12-1.56-13.744493392111.3512.459.4118043010.59259665DR
260.293.052631578959.513.149.3516600910.79951676DR
52-1.42-12.667261373811.2113.149.1523931810.57734765DR
156-6.44-39.679605668516.2317.969.1516935712.49051869DR
260-7.39-43.015133876617.1818.479.1513252013.28065336DR

ALPMY - Frequently Asked Questions (FAQ)

What is the current Astellas Pharma (PK) share price?
The current share price of Astellas Pharma (PK) is US$ 9,79
How many Astellas Pharma (PK) shares are in issue?
Astellas Pharma (PK) has 1 809 663 075 shares in issue
What is the market cap of Astellas Pharma (PK)?
The market capitalisation of Astellas Pharma (PK) is USD 17,46B
What is the 1 year trading range for Astellas Pharma (PK) share price?
Astellas Pharma (PK) has traded in the range of US$ 9,15 to US$ 13,14 during the past year
What is the PE ratio of Astellas Pharma (PK)?
The price to earnings ratio of Astellas Pharma (PK) is 1,09
What is the cash to sales ratio of Astellas Pharma (PK)?
The cash to sales ratio of Astellas Pharma (PK) is 0,01
What is the reporting currency for Astellas Pharma (PK)?
Astellas Pharma (PK) reports financial results in JPY
What is the latest annual turnover for Astellas Pharma (PK)?
The latest annual turnover of Astellas Pharma (PK) is JPY 1,62T
What is the latest annual profit for Astellas Pharma (PK)?
The latest annual profit of Astellas Pharma (PK) is JPY 17,05B
What is the registered address of Astellas Pharma (PK)?
The registered address for Astellas Pharma (PK) is 2-5-1 NIHONBASHI-HONCHO, CHUO-KU, CHUO, TOKYO, 103-8411
What is the Astellas Pharma (PK) website address?
The website address for Astellas Pharma (PK) is www.astellas.com
Which industry sector does Astellas Pharma (PK) operate in?
Astellas Pharma (PK) operates in the PHARMACEUTICAL DIVERSIFIED sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ELIQQElectriq Power Holdings Inc (CE)
US$ 0,10
(99 900,00%)
100
GNTLFGenetic Technologies Ltd (PK)
US$ 1,00
(90 809,09%)
100
VIVEViveve Medical Inc (CE)
US$ 0,0003
(29 900,00%)
7,33k
BTIMBoatim Inc (CE)
US$ 0,0002
(19 900,00%)
799
CLVRClever Leaves Holdings Inc (CE)
US$ 0,0002
(19 900,00%)
592
RAASYCloopen Group Holding Limited (CE)
US$ 0,000001
(-100,00%)
214
EWGFFEat Well Investment Group Inc (CE)
US$ 0,000001
(-100,00%)
47,01k
SOLBFSoLVBL Solutions Inc (CE)
US$ 0,000001
(-99,99%)
10k
HAVLFHavn Life Sciences Inc (CE)
US$ 0,000001
(-99,98%)
4,02k
ENDRFEndor AG (GM)
US$ 0,0001
(-99,98%)
560
HMBLHUMBL Inc (PK)
US$ 0,00095
(5,56%)
344,89M
PHILPHI Group Inc (PK)
US$ 0,0003
(0,00%)
312,21M
PLPLPlandai Biotechnology Inc (PK)
US$ 0,0001
(0,00%)
215,71M
RDARRaadr Inc (PK)
US$ 0,0014
(16,67%)
174,96M
CHNVFChina Youzan Ltd (PK)
US$ 0,0177
(10,63%)
100M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

USOTC
ALPMY
Astellas Pharma (PK)
LSE
14ME
Sp Manweb 27
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés